Myriad Genetics Inc (MYGN)

Pretax margin

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2020	Jun 30, 2019
Earnings before tax but after interest (EBT)	US$ in thousands	-262,200	-140,600	-57,100	-223,200	200
Revenue	US$ in thousands	745,400	675,200	846,000	627,800	840,000
Pretax margin		-35.18%	-20.82%	-6.75%	-35.55%	0.02%

December 31, 2023 calculation

Pretax margin = EBT ÷ Revenue
= $-262,200K ÷ $745,400K
= -35.18%

The pretax margin for Myriad Genetics, Inc. has shown significant fluctuations over the past five years. In December 2023, the company reported a pretax margin of -34.81%, indicating that its earnings before taxes were negative relative to its total revenue. This sharp decline from the previous year's pretax margin of -20.73% suggests worsening profitability performance.

Comparing to December 2021 and 2022, where the pretax margins were -8.27% and -20.73% respectively, the company's profitability deteriorated considerably by December 2023. The company also recorded a pretax margin of 0.00% in June 2019, indicating a breakeven point in profitability, which spiked to -34.97% in June 2020, signaling a significant decline in profitability in that period.

Overall, Myriad Genetics, Inc. has faced challenges in maintaining a positive pretax margin, and the negative trend observed in December 2023 raises concerns about its ability to generate profits before taxes in recent periods. Further analysis of the company's cost structure, revenue streams, and operational efficiency may be warranted to address the declining profitability reflected in the pretax margin figures.